Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health Group's revenue for the
three
months ended in Apr. 2026 was $0.13 Mil.
Its revenue for the trailing twelve months (TTM) ended in Apr. 2026 was $2.17 Mil.
Devonian Health Group's Revenue per Share for the
three
months ended in Apr. 2026 was $0.05.
Its Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $0.83.
Warning Sign:
Devonian Health Group Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Devonian Health Group was -91.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 101.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 51.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, Devonian Health Group's highest 3-Year average Revenue per Share Growth Rate was 101.80% per year. The lowest was -31.20% per year. And the median was -16.40% per year.
Devonian Health Group (OTCPK:DVHGF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Devonian Health Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Revenue distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DVHGF) has a Revenue of $2.17 Mil as of Apr. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Devonian Health Group and its competitors.
Is Devonian Health Group's Revenue too high?
Devonian Health Group's current Revenue is $2.17 Mil. Overall, Devonian Health Group has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Revenue compare to VRTX and REGN?
Devonian Health Group's Revenue of $2.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current Revenue is $2.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.00, compared to a current price of $7.00 — trading 250% above its estimated fair value. The current Revenue is $2.17 Mil. Devonian Health Group's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Revenue is $2.17 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 250% above its estimated GF Value™ of $2.00.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Revenue: $2.17 Mil
GF Value™: $2.00 vs. price of $7.00 (250% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
59GF Score
Get the complete analysis for DVHGF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
